| Abbott (23) |  |
| Amgen (10) | |
| Astra-merck (6) | |
| Bayer (41) | |
| Boehringer-ingelheim (1) | |
| Bristol-myers-squibb (5) | |
| Dupont-merck (14) | |
| Eli lilly (5) | |
| Genentech (5) | |
| Genzyme (5) | |
| Glaxosmithkline (26) | |
| Hoechst-marion-roussel (4) | |
| Pasteur-merieux (8) | |
| Pfizer (22) | |
| Pharmaceutical industry (36) | |
| Pharmaceutical laboratory (1) | |
| Pharmacyclics (1) | |
| Roche pharmaceuticals (16) | |
| Sanofi-aventis (6) | |
| Stallergenes (1) | |
| Whitehall laboratories (3) | |
The surprising result prompted Pfizer, which acquired Rinat, to explore whether the drug instead could promote weight gain,
Business Pfizer payments: On 31 march, the drug company Pfizer began to make public its payments to physicians
and other health professionals for speaking and consulting on its behalf, and for conducting clinical trials of its drugs.
Pfizer said it paid out US$35 million in the last six months of 2009. It was required to post much of the data by an agreement settling a US government investigation into the company's promotion of its drugs for off-label use.
Astrazeneca has hired Pfizer's research and development (R&d) chief, Martin Mackay, to take the helm of its own R&d programme.
Pfizer and Astrazeneca are both restructuring their R&d programmes to replenish pipelines and cut costs.
Mackay became head of R&d at Pfizer, the world's biggest drug maker, in 2007,
when Pfizer completed its acquisition of rival Wyeth. Dolsten will now lead Pfizer's R&d team alone.
Business watch A growing need to cut pharmaceutical and biotechnology research costs is fuelling a boom in the contract research organization (CRO) industry.
which includes the pharmaceutical multinationals Pfizer and Astrazeneca, will also design software to make the results useful to researchers and clinicians.
Business Pharma chiefs After four years as chief executive of New york-based drug company Pfizer, Jeffrey Kindler announced his retirement on 6 december.
The world's best-selling drug 墉 Pfizer's cholesterol-lowering medication Lipitor (atorvastatin) 墉 may face competition from generics maker Ranbaxy of Gurgaon, India.
and asked for a third to be pulled off the Market research cutback Pharmaceutical giant Pfizer on 1 february announced cuts to its research budget
Lipitor patent ends The world's best-selling drug, Pfizer's cholesterol-lowering medication Lipitor (atorvastatin) now faces competition from generics,
¢â presents recommendations for avoiding future food crises. ccafs. cgiar. org/commission Number crunch $131 bn Lifetime sales of Pfizer's cholesterol-lowering drug
and Pfizer, based in Groton, Connecticut, said on 6 Â August that they would no longer work on the monoclonal antibody bapineuzumab.
and senior vice-president at the UK-based drug firm Pfizer, died on 22 Â January. Cox s research group at Pfizer aimed to find a way to arrange clinical-trial participants on the basis of their genetic make-up.
He was also a member of one of the teams that led the Human genome Project,
At the Botanical garden's Pfizer Plant Research Laboratory they worked with Garden scientist Dr. Damon Little to generate DNA barcodes for all of the individuals
and June 2011 when an arsenic-based drug then manufactured by Pfizer and known as roxarsone was readily available to poultry companies that wished to add it to their Feed in addition to inorganic arsenic the researchers were able to identify residual roxarsone in the meat they studied;
In July 2011 Pfizer voluntarily removed roxarsone from the U s. market but the company may sell the drug overseas
Pfizer still domestically markets the arsenical drug nitarsone which is chemically similar to roxarsone. Currently in the U s. there is no federal law prohibiting the sale or use of arsenic-based drugs in poultry feed.
< Back - Next >
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011